BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Update

BioLineRx Ltd. (NASDAQ:BLRX) was the recipient of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 122,900 shares, a decline of 90.2% from the January 15th total of 1,260,000 shares. Approximately 3.3% of the shares of the stock are sold short. Based on an average daily volume of 208,100 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Investors Weigh In On BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC acquired a new stake in BioLineRx Ltd. (NASDAQ:BLRX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned about 50.50% of BioLineRx at the end of the most recent reporting period. 1.56% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BLRX has been the subject of several research analyst reports. HC Wainwright cut their price target on BioLineRx from $840.00 to $360.00 and set a “buy” rating for the company in a report on Monday, November 25th. StockNews.com started coverage on shares of BioLineRx in a research report on Tuesday, February 4th. They set a “hold” rating for the company.

BioLineRx Trading Down 1.6 %

NASDAQ BLRX traded down $0.06 during trading on Thursday, hitting $3.47. The stock had a trading volume of 36,272 shares, compared to its average volume of 419,266. The stock has a 50 day simple moving average of $6.46 and a 200 day simple moving average of $16.50. BioLineRx has a one year low of $3.24 and a one year high of $57.60. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. The stock has a market capitalization of $6.93 million, a price-to-earnings ratio of -0.39 and a beta of 1.41.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($2.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.20) by $0.40. BioLineRx had a negative net margin of 90.57% and a negative return on equity of 163.37%. Sell-side analysts predict that BioLineRx will post -5.8 earnings per share for the current year.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.